Creatine: no advantage detected for a new formulation over standard monohydrate

A different creatine formulation does not guarantee better absorption. In healthy, physically active adults, a trial comparing OptiCreatine with standard monohydrate detected no difference in blood concentrations or digestive tolerance after a single dose. However, this acute result does not establish equivalent effects on performance or over the long term.

Two samples of creatine powder next to blood collection tubes.
SupplementsEditorial illustration, not study data.

A comparison after a single dose

The study included eight men and nine women, with an average age of 22 years. In a randomized, double-blind, crossover trial, each participant received both formulations at separate visits. This design allows responses to be compared within the same people.

After an overnight fast, participants consumed a single 5-gram dose of one of the formulations. Blood samples were collected before the dose and for up to 300 minutes afterward. Digestive symptoms were assessed using validated questionnaires. These were the experimental conditions, not a dosing recommendation.

No difference detected in blood levels

Blood creatine concentrations increased with both formulations. The researchers detected no statistically significant difference between them in peak concentration, the time taken to reach it, or total blood exposure during follow-up.

Digestive symptoms were infrequent and mild under both conditions. This digestive comparison remains descriptive: the abstract does not demonstrate that OptiCreatine reduces discomfort compared with standard monohydrate.

What this result means for choosing creatine

This trial provides no evidence that OptiCreatine is superior on the blood parameters measured. But failing to detect a difference in a small sample is not enough to formally demonstrate that the products are equivalent.

Crucially, a blood concentration is not a measure of muscle creatine stores, strength, or training progress. These results therefore cannot distinguish between the formulations in terms of these benefits or their tolerability during prolonged use.

Limitations to keep in mind

Small sample of healthy, active young adults, a single dose, and follow-up limited to a few hours. Digestive symptoms were compared descriptively. Only the PubMed abstract was consulted, not the full text. Funding and conflicts of interest were not checked.

What we can take away

This study shows no acute advantage of OptiCreatine over standard monohydrate. It does not establish better athletic performance benefits or better long-term tolerability.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.